You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
Dermatology
Impact of Advanced Systemic Therapies on Disease Control in AD
Dr. Simpson discusses impact of advanced systemic therapies in AD, and the link between inhibition of type 2 inflammation and reduced IgE levels.
MD
Eric Simpson
Learning objectives
- Understand the potential of disease modification in AD, with reference to the responses achieved with various approved therapies
- Assess the impact of inhibition of type 2 inflammation and associated comorbidities, and explore as a potential avenue for disease modification
Description
Exploring the concept of disease control in AD. The discussion emphasizes the achievement of significant responses, such as EASI-90, with various approved agents, suggesting progress towards a remitted state. The discussion hovered around the potential of disease modification for sustained control over time. Lastly, the discussion explores the link between type 2 blockade and the reduction in IgE levels, suggesting a potential avenue for disease modification by influencing both the disease and associated comorbidities.
Tags
MAT-GLB-2402321- 2.0 - 01/2025
About this expert
Dermatology
Eric Simpson
MD
Professor of Dermatology, School of Medicine, Oregon Health & Science University, Portland, US
See author’s profileRelated resources
